# Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

> **NCT05845268** · PHASE2 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 102 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **COMBINATION_PRODUCT:** Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
- **COMBINATION_PRODUCT:** Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)

## Key facts

- **NCT ID:** NCT05845268
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05845268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05845268, "Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05845268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*